2023
Psychedelics, With a Focus on Psilocybin: Issues for the Clinician
Garakani A, Alexander J, Sumner C, Pine J, Gross L, Raison C, Aaronson S, Baron D. Psychedelics, With a Focus on Psilocybin: Issues for the Clinician. Journal Of Psychiatric Practice 2023, 29: 345-353. PMID: 37678363, DOI: 10.1097/pra.0000000000000729.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2021
Commentary: Diagnostic Challenges in Evaluating Adolescents
Garakani A. Commentary: Diagnostic Challenges in Evaluating Adolescents. Journal Of Psychiatric Practice 2021, 27: 239-240. PMID: 33939380, DOI: 10.1097/pra.0000000000000553.Commentaries, Editorials and LettersConceptsDiagnostic challengeConstellation of symptomsProminent mood symptomsPosttraumatic stress disorderFemale patientsTrauma-related symptomsMedication treatmentAntipsychotic medicationAdolescent patientsUnnecessary treatmentVisual hallucinationsDifferential diagnosisPatient reportsTerms of stigmaMood symptomsDepressive symptomsPsychotic symptomsSide effectsPatientsPsychotic disordersSuicidal ideasFull differential diagnosisAuditory hallucinationsCotard's syndromeIncorrect diagnosis
2020
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani A, Murrough JW, Freire RC, Thom RP, Larkin K, Buono FD, Iosifescu DV. Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Frontiers In Psychiatry 2020, 11: 595584. PMID: 33424664, PMCID: PMC7786299, DOI: 10.3389/fpsyt.2020.595584.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSerotonin-norepinephrine reuptake inhibitorsSelective serotonin reuptake inhibitorsPosttraumatic stress disorderAnxiety disordersGABAergic medicationsReuptake inhibitorsRandomized double-blind placebo-controlled trialDouble-blind placebo-controlled trialPanic disorderStress disorderSpecific phobiaBeta-adrenergic medicationsPlacebo-controlled trialCurrent pharmacological treatmentsNorepinephrine reuptake inhibitorsSerotonin reuptake inhibitorsCause of disabilityPrevalent psychiatric disordersNovel pharmacotherapeutic agentsBeta-adrenergic agentsSocial anxiety disorderMixed antidepressantsGlutamate modulatorsGlutamatergic agentsObsessive-compulsive disorder
2014
Advances in Psychopharmacology for Anxiety Disorders
Garakani A, Murrough J, Iosifescu D. Advances in Psychopharmacology for Anxiety Disorders. FOCUS The Journal Of Lifelong Learning In Psychiatry 2014, 12: 152-162. DOI: 10.1176/appi.focus.12.2.152.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSerotonin-norepinephrine reuptake inhibitorsSelective serotonin reuptake inhibitorsPosttraumatic stress disorderAnxiety disordersReuptake inhibitorsRelated conditionsGamma-aminobutyric acid (GABA) systemPharmacological treatment modalitiesFirst-line treatmentSerotonin reuptake inhibitorsNew pharmacotherapeutic approachesNorepinephrine reuptake inhibitorsVasopressin receptor antagonistsNovel treatment optionsPrevalent psychiatric disordersGlutamate modulatorsMedication classesCertain anxiety disordersNeuropeptide YTreatment modalitiesTreatment optionsNew drug developmentReceptor antagonistNew medicationsPharmacotherapeutic approaches